rabbit polyclonal anti trem1  (Proteintech)

Journal: Communications Biology

Article Title: Pan-cancer analysis reveals TREM1 + PMN-MDSCs as critical regulators of immune suppression and tumor microenvironment remodeling

doi: 10.1038/s42003-025-09342-8

Figure Lengend Snippet: A Venn diagram showing the overlap of upregulated differential genes in the TREM1 + PMN-MDSCs subset and genes reported in the literature for PMN-MDSCs. B Bar plot displaying the enriched pathways for the intersecting genes. C Density plot showing the expression of the intersecting genes. D Heatmap showing the expression of immunosuppressive genes in neutrophil subsets. E Density plot showing the expression of the TREM1 gene. F The ridge plot displaying the expression of TREM1 in the PMN-MDSCs subgroup across various cancer types that contained ≥ 10 cells in this subgroup. G Proportional plot showing the distribution of neutrophil subsets across different cancer types. H Survival analysis displaying the prognosis of TREM1 + PMN-MDSCs. I Survival analysis displaying the prognosis of the TREM1 gene. J Multiplex immunofluorescence staining for TREM1 + PMN-MDSCs. DAPI (blue), ITGAM (red), OLR1 (green) and TREM1 (magenta) are shown in individual and merged channels. The yellow arrows point to cells positive for the three markers (LUSC, lung squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma). K Compared with the T cell group, the function of T cells was inhibited after co-culture with MDSCs. When MDSCs co-cultured with tumor cells were added to T cells, the inhibition of T cell function became more significant. The statistical method used was an unpaired t -test. Error bars represent the standard error (SE). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Primary antibodies employed in this study included: Anti- CD11b antibody (Abcam, ab52478, 1:400 dilution), Rabbit Anti- LOX1 antibody (Bioss, bs-2044R, 1:400 dilution) and Rabbit Anti- TREM1 antibody (Bioss, bs-10306R, 1:400 dilution).

Techniques: Expressing, Multiplex Assay, Immunofluorescence, Staining, Co-Culture Assay, Cell Culture, Inhibition, Cell Function Assay

Journal: Communications Biology

Article Title: Pan-cancer analysis reveals TREM1 + PMN-MDSCs as critical regulators of immune suppression and tumor microenvironment remodeling

doi: 10.1038/s42003-025-09342-8

Figure Lengend Snippet: A Scatter plot showing the correlation between TREM1 + PMN-MDSCs scores and gene sets across different cancer types. B Box plot displaying the scores of gene sets in high and low infiltration groups of TREM1 + PMN-MDSCs in bulk RNA-seq. C Scatter plot showing the correlation between TREM1 + PMN-MDSCs and other gene sets in bulk RNA-seq.

Article Snippet: Primary antibodies employed in this study included: Anti- CD11b antibody (Abcam, ab52478, 1:400 dilution), Rabbit Anti- LOX1 antibody (Bioss, bs-2044R, 1:400 dilution) and Rabbit Anti- TREM1 antibody (Bioss, bs-10306R, 1:400 dilution).

Techniques: RNA Sequencing

Journal: Communications Biology

Article Title: Pan-cancer analysis reveals TREM1 + PMN-MDSCs as critical regulators of immune suppression and tumor microenvironment remodeling

doi: 10.1038/s42003-025-09342-8

Figure Lengend Snippet: A Spatial feature plots of myeloid cells, TREM1 + PMN-MDSCs, fibroblasts, along with the immunosuppressive score, in tissue sections from breast cancer (BRCA), lung cancer (LC) and kidney clear cell carcinoma (KIRC). B Enhanced spatial feature plots showing the expression of OLR1 , TREM1 and COL1A1 in tumor tissues. C MistyR analysis showing the co-localization of TREM1 + PMN-MDSC with other cell types in KIRC. D Box plot showing the expression of exhausted T cells between high and low infiltration groups of TREM1 + PMN-MDSCs in KIRC. E Scatter plot showing the correlation between TREM1 + PMN-MDSCs and fibroblasts in KIRC. F Scatter plot showing the correlation between TREM1 + PMN-MDSCs and exhausted T cells in KIRC.

Article Snippet: Primary antibodies employed in this study included: Anti- CD11b antibody (Abcam, ab52478, 1:400 dilution), Rabbit Anti- LOX1 antibody (Bioss, bs-2044R, 1:400 dilution) and Rabbit Anti- TREM1 antibody (Bioss, bs-10306R, 1:400 dilution).

Techniques: Expressing

Journal: Communications Biology

Article Title: Pan-cancer analysis reveals TREM1 + PMN-MDSCs as critical regulators of immune suppression and tumor microenvironment remodeling

doi: 10.1038/s42003-025-09342-8

Figure Lengend Snippet: A The cell‒cell interactions networks. B Scatter plots showing the strength of signal outgoing and incoming by different cell populations. C Chord plot showing the MHC-I and MIF signaling pathway networks. D Bubble plot showing ligand-receptor pairs of TREM1 + PMN-MDSCs as receivers interacting with other cell types. E Spatial feature plots showing the interaction activity of selected ligand-receptor pairs in KIRC tissue sections. F Top-ranked ligands inferred to regulate TREM1 + PMN-MDSC svia endothelial cells, fibroblasts, CD4 + Tregs, CD8 + Teffs and NK cells according to NicheNet. G Dot plot showing the expression percentage (dot size) and intensity (dot intensity) of top-ranked ligands in different cell types. H Heatmap depicting the regulatory relationships between ligands and target genes.

Article Snippet: Primary antibodies employed in this study included: Anti- CD11b antibody (Abcam, ab52478, 1:400 dilution), Rabbit Anti- LOX1 antibody (Bioss, bs-2044R, 1:400 dilution) and Rabbit Anti- TREM1 antibody (Bioss, bs-10306R, 1:400 dilution).

Techniques: Activity Assay, Expressing

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are represented as mean +/− SEM. a. TREM1 expression on myeloid cells is low under basal conditions, however with stimulation by PAMPs or DAMPs, TREM1 synergizes with innate immune receptors to amplify the pro-inflammatory response. Its functional counterpart TREM2 promotes phagocytosis and cell survival. b. Percent TREM1 surface expression across blood, spleen and brain CD45+CD11b+ myeloid cells in young (3 mo) and aged (13–17 mo) male mice. Student’s t-test, one-tailed (n=6–8 mice per group as shown). c. Multi-analyte quantification of plasma immune factors from young (3 mo) and aged (18.5 mo) WT and Trem1−/− male mice. Two-way ANOVA, effect sizes shown for genotype (Gen) and interaction (Int); post-hoc Tukey comparisons: * P < 0.05 (n=3–9 male mice/group as shown). d. Flow cytometric analysis of anti-inflammatory CD71 and pro-inflammatory MHCII and CD86 in Ly6CHi and Ly6CLo peritoneal MΦ from young 2 mo WT and aged 22–23 mo WT and Trem1−/− male mice. Two-way ANOVA, effect sizes shown for genotype and marker; post-hoc Tukey comparisons: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (n=3–5 male mice/group as shown). e. Unsupervised hierarchical clustering of significantly regulated immune factors by one-way ANOVA in cortical lysates from young wild-type (2 mo) and aged WT (25 mo) and Trem1−/− (23.5 mo) male mice, (n=5–6 male mice/group as shown). f. The Novel Object Recognition (NOR) task with habituation to testing arena, training phase with exploration of two identical objects and testing phase where object is replaced with a novel object. g. Discrimination index for the NOR task for young WT (5 mo), aged WT (18 mo) and aged Trem1−/− (18 mo) mice; paired two tailed t-test (n = 6–8 male and female mice/group as shown). h. Representative movement tracings for final training trial of the Barnes maze. Escape hole is labelled with green arrow. i. Escape latency on the Barnes maze. 2-way repeated measures ANOVA: interaction between training and genotype (F(6,120) = 7.38, P < 0.0001); Tukey’s post hoc: ***P < 0.001, ****P < 0.0001 (n= 16 young WT, 14 aged WT, and 13 aged Trem1−/− male and female mice/group).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Expressing, Functional Assay, One-tailed Test, Marker, Two Tailed Test

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: a. Gating strategy for live CD45+Cd11b+TREM1+ blood myeloid cells b. Gating strategy for live CD45+Cd11b+TREM1+ spleen myeloid cells c. Gating strategy for live CD45loCd11b+TREM1+ microglia; also includes gating for P2RY12, CD206, CX3CR1 and Tmem119 microglial markers.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Cytometry, Expressing

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are mean ±} s.e.m. unless otherwise indicated. a. Quantification of immune factors in lysates of peritoneal MF isolated from 8.5 mo WT and Trem1−/− mice treated with vehicle or 100 ng/ml LPS for 20 hr. Two-way ANOVA with Tukey’s multiple comparisons shown for WT+LPS vs Trem1−/−+ LPS (n=5–6 male mice per genotype as shown). b. Trem1 deficiency does not alter phagocytosis in peritoneal MF. Cells were stimulated with vehicle or E.coli +/− LPS 100 ng/ml for 20h. 2-way ANOVA, effect of LPS ***P < 0.001, no effect of Trem1 genotype basally or with LPS stimulation. 2–3 mo male mice with 6–11 technical replicate wells as shown.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Isolation

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are mean ±} s.e.m. unless otherwise indicated. a. Gating strategy for live Cd11b+Ly6G-CD45+Ly6CHi and Cd11b+Ly6G-CD45+Ly6CLo peritoneal MF from young WT and Trem1−/− (2 mo) and aged WT and Trem1−/− (22–23 mo) male mice. b. Representative gating for MHC II, CD86, and CD71 positive Ly6CHi peritoneal MF. c. Representative gating for MHC II, CD86, and CD71 positive Ly6CLo peritoneal MF. d. Multianalyte Luminex quantification of immune factors in young WT (2 mo) and aged WT (23–24 mo) and aged Trem1−/− (23–24 mo) cerebral cortex. One-way ANOVA with Tukey’s multiple comparisons shown (n=5–6 male mice per group as shown). e. Total time exploring (in seconds) during the training phase of the NOR task; ANOVA with Tukey’s multiple comparisons show no significant differences (n=6–8 female mice as shown). f. Speed (pixels/second) of mice during the final trial of the Barnes Maze; ANOVA with Tukey’s multiple comparisons (n=5–6 male and female mice as shown).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Luminex

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are mean ± s.e.m. unless otherwise indicated. a. Volcano plot of DEGs from aged (18 – 20 mo) vs young (3 mo) CD45lowCD11b+ microglia with −log10(P) > 1 after FDR adjustment and log2 fold change > 1. n=3 samples/age (each sample pooled from 2 male mice). b. Volcano plot of DEGs from aged Trem1−/− vs aged WT microglia with −log10(P) > 1.25 after FDR and log2 fold change > 1. n=3 samples/genotype (each sample pooled from 2 male mice). c. Unsupervised hierarchical clustering of DEGs from mouse peritoneal MΦ from young WT (2 mo), aged WT (25 mo) and aged Trem1−/− (25 mo) mice. Scale represents z-score values of FPKM (n=3–4 male mice/group). d. Unsupervised hierarchical clustering of cytokine and chemokines DEGs (q < 0.05). Scale represents z-score values from FPKM (n=3–4 mice/group). e. Pathway enrichment analysis of DEGs in the Mouse MitoCarta3.0 gene list. Scale represents Log(p) × fold enrichment (FE). f. Representative oxygen consumption rate (OCR) traces with SeaHorse for young (4.5 mo) and aged (22–23 mo) wild-type (WT) and Trem1−/− peritoneal MΦ (n= 5 male mice/group). Arrowheads indicate application of electron transport-chain inhibitors. Abbreviations: olig: oligomycin, FCCP: carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone, rot/ant: rotenone/antimycin A (n=5 male mice/group). g. Quantification of basal respiration and glycolysis (extracellular acidification rate, or ECAR) for young (4.5 mo) and aged (22–23 mo) WT and Trem1−/− peritoneal MΦ. Two-way ANOVA, Tukey’s multiple comparisons shown; effect of age, P<0.0001 and genotype, P=0.0001 (OCR, n=3 male mice/group; ECAR, n=3 male mice/group). h. Transmission electron microscopy (TEM) images of young (4.5 mo) and aged (24–26 mo) Trem1−/− and WT peritoneal MΦ. Yellow arrows indicate mitochondria. Abbreviations: M: mitochondrion; N: nucleus. Scale = 1 μm. i. Numbers of MΦ mitochondria and percent abnormal mitochondria from (h). Two-way ANOVA, Tukey’s multiple comparisons shown; effect of age, P=0.0021; genotype, P=0.0005; interaction, P=0.0008 (n= 3–5 male mice/group). j. Mitochondrial superoxide production in peritoneal MΦ, normalized to MitoTracker signal, in young (4 mo) and aged (20 mo) male WT and Trem1−/− mice, n=8 mice/group. Two-way ANOVA with Tukey’s multiple comparisons test; effect of age, P<0.0001; genotype, P=0.0012; interaction, P=0.0289.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Transmission Assay, Electron Microscopy

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: a. Venn diagram of DEGs (all genes q < 0.05) in pairwise comparisons of microglia isolated from aged (18 – 20 mo) vs young (3 mo) mice and pairwise comparisons of microglia isolated from aged Trem1−/− vs aged WT mice (18–20 mo). Blue indicates number of downregulated genes while red indicates the number of upregulated genes (n=3 microglial samples (2 pooled male mice per sample) per group). b. KEGG Pathway enrichment analysis of upregulated genes in aged compared to young microglia; there were no enriched pathways in the comparison of aged WT vs aged Trem1−/− microglia. c. Venn diagrams showing the number of DEGs (all genes q < 0.05) in pairwise comparisons of primary mouse MF from young WT (2 mo), aged WT (25 mo) and aged Trem1−/− (25 mo) mice. Blue indicates number of downregulated genes while red indicates the number of upregulated genes (n=3–4 male mice per group). d. Pathway enrichment analysis of upregulated genes in aged MF vs young and in aged Trem1−/− vs aged WT MF. e. Heatmap of DEGs (q < 0.05) comprising the Coordinated Lysosomal Expression and Regulation (CLEAR) network. Lysosomal functional categories are indicated for each gene. Aged Trem1−/− mice cluster with the young WT mice. Scale represents z-score values from FPKM. n=3–4 male mice per group.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Expressing, Isolation, Comparison, Functional Assay

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: a. PCA of metabolites from young (2 mo) WT and Trem1−/− peritoneal MF (n=3 male mice per group). b. PCA of significantly regulated metabolites from primary peritoneal MF isolated from young WT (2mo), aged WT (25 mo) and aged Trem1−/− (25 mo) male mice. n=3–5 male mice per group. c. Volcano plot comparing aged WT vs young WT (left) and aged Trem1−/− vs aged WT (right) peritoneal MF with Log2 fold change (FC) and -Log10(P) values of metabolites. Significantly regulated metabolites with -log10(P) > 2 and log2 fold change > 1 are shown in blue. d. KEGG metabolic pathway enrichment analysis of differentially regulated metabolites between aged WT and young WT macrophages and between aged Trem1−/− vs aged WT MF. X-axis shows -Log10(q) value. No pathways were significant following FDR correction for the comparison of aged Trem1−/− vs young WT. Pathway analysis was performed using MetaboAnalyst 5.0; n=3–5 male mice per group. e. Total ion count of Ribose-5P, the precursor of purines and pyrimidines and total ion counts for nucleobases and derivatives, ribo-nucleosides, deoxynucleosides, and nucleoside monophosphates. Data are analyzed by one-way ANOVA with Tukey’s multiple comparisons (n=3–5 male mice per group). Abbreviations: AMP: adenosine monophosphate, GMP: guanosine monophosphate, UMP: uridine monophosphate, CMP cytidine monophosphate, IMP: inosine monophosphate. n=3–5 male mice per group as shown. f. Transcription factor (TF) enrichment analysis revealing TFs enriched for differentially expressed metabolite enzymes. g. FKPM of NRF2. ANOVA followed by Tukey’s multiple comparison (n=3–4 male mice per group as shown). h. FKPM of the 3 pyruvate dehydrogenase complex (PDH) subunits: pyruvate dehydrogenase (PDHA1), dihydrolipoyl transacetylase (DLAT) and dihydrolipoyl dehydrogenase (DLD); one-way ANOVA followed by Tukey’s multiple comparison (n=3–4 male mice per group as shown).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Isolation, Comparison

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: a. Unsupervised hierarchical clustering of significantly regulated metabolites from peritoneal MΦ isolated from young WT (2 mo), aged WT (25 mo) and aged Trem1−/− (25 mo) male mice. TREM1-deficient MΦ cluster with young WT MΦ. Data were analyzed and clustered using MetaboAnalyst 5.0; n=3–5 male mice per group as shown. b. Metabolic pathway map of glycolysis, pentose phosphate pathway (PPP), TCA cycle, and purine and pyrimidine synthesis demonstrates decrease of Ribose 5-Phosphate (R5P), the precursor of purine and pyrimidine synthesis, in aged WT MΦ that is restored to young WT levels with Trem1 deletion. Colored circles represent z-scored fold change levels for significantly modified metabolites. Yellow circles indicate no significant difference. Small gray circles indicate metabolites that were not measured. c. Integration of transcriptomic and metabolomic features demonstrates enrichment in purine and pyrimidine metabolism. Included in the joint pathway analysis were differentially regulated metabolites (q < 0.05) and the highest regulated DEGs (q-values < 0.05 and Log2FC > +/−2) and fold change for each feature. No pathways were enriched in the comparison between aged Trem1−/− and young WT. Data were analyzed using the Joint Pathway Analysis function in MetaboAnalyst 5.0. d. Glycolysis and PPP enzymes (blue) with FPKM quantification. 1-way ANOVA with Tukey’s multiple comparisons shown (n=3–4 male mice/group as shown). Abbreviations: 6PGD: 6-phosphogluconate dehydrogenase; G6PD: glucose-6-phosphate dehydrogenase; HK1: hexokinase-1, PK: pyruvate kinase; RPI: ribose-5-phosphate isomerase. Enzymes G6pdx, 6Pgd, Rpia, Taldo1 and Pkm are known NRF2 target genes. Data are shown as mean ± s.e.m. e. Immunofluorescent localization of NRF2 in CD11b+ peritoneal MΦ isolated from (4.5 mo) and aged (24–26 mo) WT and Trem1−/− male mice. f. Quantification of total NRF2 levels in MΦ from (e). 3–5 confocal images were processed per cell using ImageJ. 2-way ANOVA, Tukey’s multiple comparisons test shown (n=3–6 male mice/group as shown). Data are shown as mean ± s.e.m.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Isolation, Modification, Comparison

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are shown as mean ± s.e.m. a. OCR traces from postnatal mouse microglia from WT and Trem1−/− mice stimulated with vehicle or Aß42 oligomers (100 nM) for 20 hours (n=5 wells per genotype/condition). b. Quantification of basal respiration and glycolysis (ECAR). Two-way ANOVA with Tukey’s multiple comparisons; for basal respiration, effect of genotype and interaction, P=0.0006; for ECAR, effect of genotype, Aß, and interaction, P<0.0001 (n=5 wells per genotype/condition). c. Percent TREM1+CD45loCD11b+microglia in WT vs 5XFAD mice (n=6–8 male and female mice/group as shown, 13–17 mo) d. Novel Object Recognition (NOR) of 6–7 mo WT, 5XFAD and 5XFAD;Trem1+/− mice. Training (clear circles) and testing (green circles) discrimination index differences were assessed with paired t-tests. Discrimination index of 0.5 indicates chance preference (n=11–12 male and female mice/condition). e. Escape latency of 5XFAD cohorts on the Barnes maze. 2-way repeated measures (RM) ANOVA with Tukey’s multiple comparisons. Interaction between training and mouse genotype [F(6,90) = 4.14, P < 0.001)] (n=11 WT, n=12 5XFAD, n=10 5XFAD;Trem1+/− male and female mice/group). f. Mean integrated density of 6E10 signal from hippocampal CA1 of 9–10 mo 5XFAD and 5xFAD;Trem1+/− mice (n=6 female mice/group). g. Mean integrated density of ThioS signal, a marker of fibrillar amyloid, from CA1 of 9–10 mo 5XFAD and 5xFAD;Trem1+/− mice (n=5–7 female mice/group). h. Unsupervised hierarchical clustering of significantly regulated immune proteins in hippocampus from 9–10 mo WT, 5XFAD, and 5XFAD;Trem1+/− mice, one-way ANOVA (n=5–6 female mice/group). i. Immunofluorescent images of Iba1+ microglia and 6E10 staining of amyloid in CA1 of 9–10 mo WT, 5XFAD, and 5XFAD;Trem1+/− female mice and 3-dimensional rendering of representative microglia. Scale bar is 25μm (top row) and 10 μm (bottom row). j. Quantification of average microglial branch length and maximum branch length. One-way ANOVA with Tukey’s multiple comparison (n=5 female mice/group). k. Heatmap depicting group means of significantly regulated (one-way ANOVA) DAM signature genes. Microglia samples were pooled from two 6–7 mo male mice (n=3 samples per genotype). Scale represents z-score values from FPKM. l. Neuritic dystrophy visualized with anti-BACE1 immunostaining at X34+ amyloid plaques in WT, 5XFAD, and 5XFAD;Trem1+/− 9–10 mo female mice; scale bar=10 μm m. Quantification of BACE1-positive percent area around amyloid plaques. One-way ANOVA with Tukey’s multiple comparisons (n= 5–6 female mice/group). n. Quantification of plasma immune factors in WT, 5XFAD, and 5XFAD;Trem1+/− 9–10 mo mice. One-way ANOVA with Tukey’s multiple comparisons (n= 4–6 female mice/group).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Marker, Staining, Comparison, Immunostaining

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are mean ±} s.e.m. unless otherwise indicated. a. (Left) Immunofluorescent staining of TREM1 in 9 mo WT and APPSwe-PS1ΔE9 hippocampal stratum lacunosum in IBA1+microglia. 5–7 hippocampal sections per mouse were imaged, n=5 10 male mice/genotype. Scale bar = 10 μm. TREM1 colocalizes with Iba1+ cells (white arrows). (Right) Quantification of MFI. b. Thioflavin-S (ThioS) fluorescent staining of hippocampus in 9–10 mo 5XFAD and 5XFAD;Trem1+/− female mice. Scale bar = 500 μm. c. Soluble levels of cerebral cortical As40 and 42 and the ratio of As42/40 in 5X FAD and 5XFAD;Trem1+/− mice. Student’s two tailed t-test (n=4–6 males/group as shown, 10–13 mo) d. Insoluble levels of cerebral cortical As40 and 42 and the ratio of As42/40 in 5X FAD and 5XFAD;Trem1+/− mice; Student’s two tailed t-test (n=4–6 males/group as shown, 10–13 mo) e. Quantification of hippocampal immune factors in WT, 5XFAD, and 5XFAD;Trem1+/− 10 mo mice. One-way ANOVA with Tukey post-hoc comparisons (n= 5–6 female mice per group as shown). f. Microglial number from Fig. 4i. One-way ANOVA with Tukey’s multiple comparisons (n=5 male mice per condition).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Staining, Two Tailed Test

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are mean ±} s.e.m. unless otherwise indicated. a. PCA of significantly regulated DAM signature genes from primary microglia isolated from WT, 5XFAD and 5XFAD/Trem1+/− mice. Individual microglial samples were pooled from 2 male mice (n=3 samples per condition). b. Hierarchical clustering of DAM signature gene set showing homeostatic, DAM Stage 1 and DAM Stage 2 genes. Scale represents z-score values from FPKM. c. Hierarchical clustering of top 170 DEGs (FDR-corrected) belonging to the full DAM signature gene set. Scale represents z-score values from FPKM. Scale represents z-score values from FPKM. d. (Left) Percent of CX3CR1+ microglia in young (3 mo) and 13–17 mo WT, 5xFAD and 5xFAD;Trem1+/− mice. (Right) MFI of CX3CR1+ microglia. One-way ANOVA with Tukey’s multiple comparison, not significant (n= 5–8 male and female mice per group as shown). e. (Left) Percent of Tmem119+ microglia in young (3 mo) and 13–17 mo WT, 5xFAD and 5xFAD;Trem1+/− mice. (Right) MFI of Tmem119+ microglia. One-way ANOVA with Tukey’s multiple comparisons (n=4–5 mice per group). f. (Left) Total time exploring (in seconds) during the training phase of the NOR task in APPSwe mice; ANOVA with Tukey’s post-hoc test (n=14–17 male and female mice per condition as shown). g. Motor speed (pixels/sec) during the final training session of the Barnes maze; ANOVA with Tukey’s post-hoc test (n=6 male and female mice per group). h. Distance traveled during the final training session of the Barnes maze; ANOVA with Tukey’s post-hoc test (n=6 male and female mice per group). i. Coupling assay tracings of synaptic mitochondria oxygen consumption rates (OCR). Shown over time are the rates of basal Complex II respiration, State III (ADP stimulated respiration), State IV (oligomycin) and State IIIu (State III uncoupled, FCCP) that were consecutively measured over the course of the assay (n=5–9 male mice per condition). j. Diagram of model of action of TREM1 in aging and transgenic mice with amyloid accumulation. In aging, peripheral TREM1 activity contributes to declines in myeloid metabolism and immune functions that lead to age-dependent cognitive decline. In models of amyloid accumulation, both peripheral and microglial TREM1 contribute to cognitive deficits associated with local accumulation of amyloid.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Isolation, Comparison, Transgenic Assay, Activity Assay

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are shown as mean ± s.e.m. a. Discrimination index during the NOR task for aged (18–21 mo) APPSwe, APPSwe/Trem1+/− and APPSwe/Trem1−/− mice; paired t-test of Training vs. Testing (n=11–17 male and female mice/group as shown). b. Escape latency of APPSwe cohorts in the Barnes maze. 2-way repeated measures ANOVA with Tukey’s multiple comparisons. Interaction between training and mouse genotype [F(6,132) = 12.24, P < 0.0001)] (n=17 APPSwe, 14 APPSwe/Trem1+/− and 16 APPSwe/Trem1−/− male and female mice/group). c. Percent area positive for 6E10 in hippocampus of 18–21 mo APPSwe and APPSwe;Trem1−/− mice. Student’s two tailed t-test (n=5–7 male/female mice/group as shown). d. Average integrated density for ThioS+ signal in hippocampus of 18–21 mo APPSwe and APPSwe;Trem1−/− mice. Student’s two tailed t-test, n=5–8 male/female mice/group as shown. e. Hippocampal immune factors in 20–23 mo in WT, APPSwe, APPSwe/Trem1+/− and APPSwe/Trem1−/− mice. One-way ANOVA with Tukey’s multiple comparisons (n=4–9 female mice/group as shown). f. Plasma cytokines in 20–23 mo in WT, APPSwe, APPSwe/Trem1+/− and APPSwe/Trem1−/− mice. One-way ANOVA with Tukey’s multiple comparisons (n=4–9 female mice/group as shown). g. Respiratory control ratio (RCR) in synaptic mitochondria fractions from 18–24 mo mouse brain. High RCR indicates mitochondria with a high capacity for substrate oxidation and ATP turnover and a low proton leak. One-way ANOVA with Tukey’s multiple comparisons (n=5–9 male mice/group as shown). h. Synaptic mitochondria OCR (pmol/min) calculated basally and for state III, state IVo, and state IIIu in 18–24 mo WT, APPSwe and in APPSwe;Trem1−/− mice. State III reflects maximal ADP-stimulated respiration and State IV reflects the return to a basal state of respiration after addition of ATP synthase inhibitor oligomycin. One-way ANOVA with Tukey’s multiple comparisons (n=5–9 male mice/group as shown). i. Representative coronal brain [18F]FDG-PET/CT images of cerebral glucose metabolism in 17–19 mo female mice. SUV: standardized uptake values. Static 20 min PET images were acquired at 75–95 min following [18F]FDG injection. j. Quantification of [18F]FDG-PET signal in hippocampus and thalamus. SUVs were normalized to individual blood glucose concentrations. One-way ANOVA with Tukey’s multiple comparisons (n=5–9 female mice/group).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Two Tailed Test, Positron Emission Tomography-Computed Tomography, Injection

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: Data are shown as mean ± s.e.m. unless otherwise indicated. a. Immunofluorescent staining of human frontal cortex for TREM1 (red), Iba1 (green), and X-34 (blue). TREM1+/Iba1+ cells are defined as plaque associated (within 15 μm of an X-34+ amyloid plaque) or non-plaque associated. Scale bar = 20 μm. White arrows indicate colocalization of Iba1 and TREM1. b. Quantification of TREM1+/Iba1+ plaque-associated and non-plaque-associated cells. One-way ANOVA with Tukey’s multiple comparisons. n=5 AD donors and n=3 Control donors. c. Immunoblot of TREM1 and TREM2 in middle frontal gyrus across clinicopathological diagnoses (n=11–12 donors/group). d. Quantification of TREM1 and TREM2 protein normalized to ß-actin and expressed as fold-change over non-demented control. ANCOVA with Tukey’s multiple comparisons. Age and sex were included as covariates (n=11–12 donors/group). e. Linear regression analyses between amyloid plaque and neurofibrillary tangle (NFT) density and TREM1 (left plot) and TREM2 (right plot) levels from quantitative immunoblotting. Model was adjusted for age and sex. Plotted are the 95% confidence bands of the best-fit line from the linear regression. The standardized regression coefficients (ß) and P-values from the linear model are shown. n=43 donors (amyloid plaque density vs TREM1) and n=42 donors (amyloid plaque density vs TREM2). f. Linear regression analyses between neurofibrillary tangle (NFT) density and TREM1 (left plot) or TREM2 (right plot) levels from quantitative immunoblotting; n=41 donors (NFT density vs TREM1) and n=40 donors (NFT density vs TREM2). g. Mendelian Randomization (MR) analysis of relationship between plasma levels of soluble TREM1 (sTREM1; exposure) and Alzheimer’s disease risk (outcome). Blue lines are estimated MR-inverse variance weighted effects, and dashed lines indicate the 95% confidence interval for MR effects. Increased plasma sTREM1 level was associated with increased AD risk (β = +0.0929, [95% CI = 0.019 to 0.166] P = 0.013). h. Mendelian Randomization (MR) analysis showing relationship between plasma levels of soluble sTREM2 (as exposure) and Alzheimer’s disease risk (outcome). Increased plasma sTREM2 level was associated with decreased AD risk (β = −0.15 [95% CI = −0.223 to −0.077] P = 5.61×10−05).

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Staining, Western Blot

Journal: Nature neuroscience

Article Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer’s disease mouse models

doi: 10.1038/s41593-024-01610-w

Figure Lengend Snippet: a. Immunofluorescent staining of human frontal cortex without addition of TREM1 antibody and secondary only control (red), Iba1 (green), and X-34 (blue) signal. This antibody validation experiment was performed three times. Scale bar = 20 μm. b. Immunoblot of TREM1 protein in postmortem human mid frontal gyrus. Clinicopathological diagnoses: non-demented Braak I-II, demented non-AD Braak stages I-II, AD Braak III-IV and AD Braak V-VI. Primary antibody detected human TREM1 band at the molecular weight of positive control (human liver lysates, Cat# HT-314, Zyagen, San Diego, CA). The TREM1 band used for analysis are indicated by blue box. Also shown is the band for s-actin at 42 kDa. This antibody validation experiment was performed once. c. Immunoblot of TREM2 protein in postmortem human mid frontal gyrus. Primary antibody detects human TREM2 band at the molecular weight of positive control (human liver lysates, Cat# HT-314, Zyagen, San Diego, CA). TREM2 bands used for analysis are indicated by blue box. Also shown is the band for s-actin at 42kDa. This antibody validation experiment was performed once. d. Mendelian Randomization (MR) analyses with Alzheimer’s disease (AD) risk level as exposure and sTREM1 plasma protein level as outcome. Blue lines are estimated MR-median weight effects, and the dashed lines indicate the 95% confidence interval for the MR effects. e. Mendelian Randomization (MR) analyses with AD risk level as exposure and TREM2 plasma protein levels as outcome. Blue lines are estimated MR-median weight effects, and the dashed lines indicate the 95% confidence interval for the MR effects.

Article Snippet: Sections were then incubated overnight in rabbit polyclonal anti-TREM1 (Cat# 93717, Abcam, 1:150, 93717) and anti-Iba1 (Cat# ab5076, Abcam) in 5% NDS in PBS with 0.4% Tween.

Techniques: Expressing, Staining, Western Blot, Molecular Weight, Positive Control

Journal: Cancer reports (Hoboken, N.J.)

Article Title: Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.

doi: 10.1002/cnr2.2007

Figure Lengend Snippet: FIGURE 13 Immunohistochemical analysis of ICD-related genes. (A) The representative images of IHC staining for DDX58 and TREM1 in TNBC and adjacent non-tumor tissues (200). (B) Quantification of A. *p < .05. (C) The representative images of IHC staining for DDX58 and TREM1 from Human Protein Atlas.

Article Snippet: After deparaffinization and hydration, the slices were incubated overnight at 4 C with primary antibodies, including mouse anti-DDX58 monoclonal antibody (1:200, TA506141S; ORIGENE) and rabbit anti-TREM1 polyclonal antibody (1:100, TA369422S; ORIGENE), followed by incubation with secondary antibodies conjugated with horseradish peroxidase.

Techniques: Immunohistochemical staining, Immunohistochemistry

Journal: Cancer Reports

Article Title: Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer

doi: 10.1002/cnr2.2007

Figure Lengend Snippet: Immunohistochemical analysis of ICD‐related genes. (A) The representative images of IHC staining for DDX58 and TREM1 in TNBC and adjacent non‐tumor tissues (200×). (B) Quantification of A. * p < .05. (C) The representative images of IHC staining for DDX58 and TREM1 from Human Protein Atlas.

Article Snippet: After deparaffinization and hydration, the slices were incubated overnight at 4°C with primary antibodies, including mouse anti‐DDX58 monoclonal antibody (1:200, TA506141S; ORIGENE) and rabbit anti‐TREM1 polyclonal antibody (1:100, TA369422S; ORIGENE), followed by incubation with secondary antibodies conjugated with horseradish peroxidase.

Techniques: Immunohistochemistry

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: TREM1 expression profiles in normal tissues and tumors. ( A ) Expression level of TREM1 between tumor and normal tissues in pan-cancer according to the integrated data from GTEx and TCGA datasets. ( B ) mRNA expression of TREM1 in KIRC, BLCA and BRCA patients assessed by qRT-PCR analysis. ( C ) Protein expression of TREM1 detected by Western blot in paired KIRC and adjacent normal tissues. ( D ) Western blot protein detection of theTREM1 expression levels in paired normal tissues and BLCA (left panel), BRCA (right panel) tissues. ( E ) IHC of TREM1 in paired KIRC and adjacent normal tissues.

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques: Expressing, Quantitative RT-PCR, Western Blot

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: Prognostic value of TREM1 in TCGA pan-cancer. K-M curves of overall survival stratified by the low- and high-expression of TREM1 in indicated cancers. Log rank test was applied to calculate the P values.

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques: Expressing

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: Mutation landscape of TREM1 in pan-cancer. ( A and B ) Mutation frequency ( A ) and general mutation count ( B ) of TREM1 in multiple TCGA pan-cancer studies according to the cBioPortal database. ( C ) Mutation diagram of TREM1 across protein domains in various cancers. ( D ) Correlations between TREM1 expression and DNA methylation in pan-cancer. ( E – G ) Correlations between TREM1 expression and TMB ( E ), MSI ( F ), and NEO ( G ) in pan-cancer.

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques: Mutagenesis, Expressing, DNA Methylation Assay

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: Correlations between TREM1 expression and immune cell infiltration abundance in cancers. ( A ) Heatmap displaying the correlations between TREM1 expression and infiltration levels of 22 immune cells calculated by CIBERSORT in pan-cancer. ( B ) Heatmap displaying the correlations between TREM1 expression and estimate scores in pan-cancer. * P < 0.05, ** P < 0.01, *** P < 0.001. Abbreviation list of tumor cohorts from TCGA is given in Table S1 .

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques: Expressing

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: Exploration of the relationship between TREM1 and immune components based on ssGSEA algorithm. ( A ) Butterfly plot displaying the correlation between TREM1 and TME-related signatures (left panel), KEGG terms, and GO terms (right panel) in KIRC. ( B and C ) Correlations between TREM1 expression and ssGSEA scores of hallmark ( B ) or TME ( C ) gene sets in TCGA pan-cancer.

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques: Expressing

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: Predictive value of TREM1 in immunotherapy efficacy. ( A and B ) Kaplan–Meier survival curve of PFS between high- and low-TREM1 subgroups in the IMmotion150 cohort ( A ) and the IMmotion151 cohort ( B ). ( C and D ) Kaplan–Meier survival curve of OS between high- and low-TREM1 subgroups in the CheckMate cohort ( C ) and the IMvigor210 cohort ( D ). Log rank test was applied to calculate the P values. ( E ) Bar charts representing the proportion of patients in high- and low-TREM1 subgroups that responded to immunotherapy in the IMmotion150 cohort. ( F ) Bar charts representing the proportion of patients in high- and low-TREM1 subgroups that responded to immunotherapy in the IMvigor210 cohort.

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques:

Journal: Journal of Inflammation Research

Article Title: Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

doi: 10.2147/JIR.S398284

Figure Lengend Snippet: Therapeutic response prediction based on pRRopheticPredict and Connectivity Map analysis. ( A ) Boxplot displaying difference of the sensitivities to the chemotherapy drugs between patients with a high expression of TREM1 and a low expression of TREM1 in KIRC. ( B ) Heatmap showing predicted score (positive in red, negative in blue) of top 60 compounds (30 negatively correlated and 30 positively correlated) from the Connectivity Map for indicated cancer type. KIRC, Kidney renal clear cell carcinoma. Abbreviation list of tumor cohorts from TCGA is given in Table S1 .

Article Snippet: The following primary antibodies were used in Western blot or IHC: anti-Vinculin rabbit polyclonal antibody (26520-1-AP, Proteintech), anti-TREM1 rabbit polyclonal antibody (11791-1-AP, Proteintech).

Techniques: Clinical Proteomics, Expressing